The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Maintenance therapy in CTCL
Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, talks on the benefits of administering maintenance therapy in the management of cutaneous T-cell lymphoma (CTCL), highlighting how high tumor burden means that complete remission rates are low, and commenting on the use of agents such as bexarotene and interferons. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
